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EcoNomIc EvaluatIoNs IN INfEctIous dIsEasE: whIch INfEctIoNs, what 
sEttINgs aNd what tyPE of EcoNomIc EvaluatIoNs wErE rEPortEd IN 
PaPErs PublIshEd IN 2014?
Martin A
Crystallise Ltd., London, UK
Objectives: To determine the focus of economic evaluation papers relevant to 
infectious diseases that were indexed in the PubMed database and published in 
2014. MethOds: An evidence surveillance process was established based on a 
systematic search of PubMed, using key words relevant to economic modelling in 
healthcare or disease and limited to studies published in English, in humans, and 
with abstracts. Articles were included if they analysed the cost-effectiveness of 
interventions, healthcare service design or methodological issues related to one 
or more infectious disease. We included all studies with a publication date of 2014 
that were indexed in PubMed up to 8 June 2015. Results: The search identified 
2,772 articles published in 2014. Of these, 148 were conducted in patients with 
infectious diseases. Most (32 articles) were in HIV-infected people, 14 articles were 
in those with hepatitis C, 13 in tuberculosis, 9 in human papilloma virus infec-
tion, 7 in pneumonia, and 6 each in influenza and hepatitis B. Twenty-five analyses 
were set in African countries, mainly on HIV (11 articles) and malaria (4). The 24 
analyses in Asia were more diverse, with only 3 each on HIV and tuberculosis. 
The 30 European analyses were also diverse, with 5 on hepatitis C, 4 each on HIV 
and pneumonia, and 3 on hospital-acquired infections. Of the 35 North American 
analyses, 8 related to hospital-acquired infections, 6 to hepatitis C, 4 to hepatitis 
B, and only 2 each on HIV or tuberculosis. Cost-utility analyses were reported in 
58 articles and cost-effectiveness in 43, and only 11 abstracts stated that indirect 
costs were modelled. cOnclusiOns: Infectious diseases were the most common 
disease class to be evaluated for cost-effectiveness in our search for studies pub-
lished in 2014, with a geographical focus that reflects the relevant epidemiology. 
Despite potential societal costs from pandemics or chronic infection, evaluations 
rarely considered indirect costs.
PIN78
PharmacoEPIdEmIologIc modElINg of trEatmENt hIv-INfEctEd 
PatIENts wIth rIlPIvIrINE/ tENofovIr/ EmtrIcItabIN (sINglE tablEt 
rEgImEN) IN russIa
Yagudina R, Kulikov A, Babiy VV,
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To obtain potential pharmacoepidemiologic outcomes of rilpivirine/ 
tenofovir/ emtricitabin (single tablet regimen) in treatment of naïve patients with 
HIV-1 RNA< 100 000 copies/ml in the Russian Federation. MethOds: The developed 
model was by nature a mathematical one. It was based on published data from 
international researches (efficacy data), from local researches in Eastern Europe 
(data on probability of death and disease progression, sexual behavior), and from 
researches in the Russian Federation (data on HIV-infected patient population, life 
expectancy etc.). The model included analysis of viral transmission via sexual con-
tact and/or injection drug use. The influence of character of sexual contact, condom 
effectiveness and efficacy of three schemes of highly active antiretroviral treat-
ment was taken into account. The time-horizon was 5 years. Results: Treatment of 
naïve HIV-infected patients with rilpivirine/ tenofovir/ emtricitabin leads to poten-
tial smaller number of new infected persons in long term perspective than with 
efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir + tenofovir/ 
emtricitabin (multi-pill regimen) by a term of order 13% (9570 new HIV-patients 
less) and 10% (7262 new HIV-patients less), respectively. cOnclusiOns: Obtained 
results approves the use of rilpivirine/ tenofovir/ emtricitabin (single tablet regimen) 
in similar to analyzed patient populations due to the potential lower number of new 
HIV-patients as compared to multi-pill regimens: efavirenz + tenofovir/ emtricitabin 
and lopinavir + tenofovir/ emtricitabin.
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thE EPIdEmIologIcal aNd cost burdEN of hErPEs ZostEr (hZ) aNd Post-
hErPEtIc NEuralgIa (PhN) IN thE uk
Taieb V1, Schwarzbard J1, Butt T2, Gama J2, Gauthier A1, Gallagher E2
1Amaris, London, UK, 2Sanofi Pasteur MSD, Maidenhead, UK
Objectives: This retrospective database analysis aimed to update epidemiologi-
cal and cost estimates related to HZ and PHN in adults from the perspective of 
the UK National Health Service (NHS). MethOds: Adults (18+) diagnosed with HZ 
between 2006 and 2013 were identified from The Health Improvement Network 
(THIN) linked to the Hospital Episode Statistics (HES) database. Unit costs were 
assigned from the British National Formulary, PSSRU Unit Costs of Health and 
Social Care and NHS Payment Grouper. Results: 27,362 patients with HZ were 
identified, corresponding to an incidence of 4.12% in the adult population. Average 
age at HZ diagnosis was 60.4. 137,674 HZ cases occurred in immunocompetent 
patients aged 50 or more. 21% of HZ patients developed PHN at least 3 months 
after HZ diagnosis. The mean duration of PHN was 13 months. In the first month 
of diagnosis, the mean cost of HZ per patient was £65.5 (61% visits, 29% medica-
tions, 10% hospitalisations). The mean cost of PHN per patient was £921 (63% visits, 
37% medications and less than 1% hospitalisations), the mean monthly cost was 
£58.7. The total cost associated with incident cases of HZ and PHN over a year 
was estimated at £52,543,827 in the UK. PHN was the most important driver of 
cost (72% of total). cOnclusiOns: This study re-affirms the significant burden 
of HZ and PHN on the UK health care system and shows that the mean age of HZ 
onset is significantly lower than current recommended age for HZ vaccination.
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PublIc hEalth aNd EcoNomIc bENEfIts of QuadrIvalENt INfluENZa 
vaccINE IN PaNama
Jamotte A1, Caicedo Navas AG2, Macabeo B3, Lopez JG4, Moreno B5, Franco D5, Garcia LN6, 
Isaza de Molto Y6
from SPRING-2, SINGLE and FLAMINGO trials, each one of them went through a 
Markov chain to emulate each patient life from initial treatment to death. The 
health states included were: living with HIV with or without opportunistic infec-
tions, long-term chronic diseases and death. Transition probabilities for each 
1-month cycle, were obtained from clinical trials. Utilities and direct health-care 
costs (€ 2015) were obtained from literature and national databases. A 3% annual 
discount was applied to costs and health outcomes. Sensitivity analysis with 0% 
and 5% discount rates were performed. Results: Treatment initiation with DTG/
ABC/3TC was dominant when it was compared with treatment initiation with all 
the comparators: vs. FTC/TDF/EFV (-67,210.71€ /QALY), vs. DRV/r + FTC/TDF or 
ABC/3TC (-152,411.73€ /QALY), and vs. RAL + FTC/TDF or ABC/3TC (-182,480.19€ /
QALY). All the sensitivity analyses performed showed the consistency of these 
findings. The main driver of cost was ATR-treatment (about 80%) followed by the 
costs of care (around 14%). cOnclusiOns: With the premises considered, treat-
ment initiation with DTG/ABC/3TC STR appears to be the most cost-effective 
option in ART-naïve HIV infected patients from the Spanish Health System per-
spective.
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gENotyPE 1 or 4 chroNIc hEPatItIs c IN ENglaNd aNd walEs
Howells R1, Treharne C2
1Abacus International, Manchester, UK, 2Abacus International, Bicester, UK
Objectives: Ledipasvir/sofosbuvir (LDV/SOF; Harvoni) is a new oral single table 
regimen for the treatment of chronic hepatitis C (CHC) in adults. This study 
assessed the cost-effectiveness of LDV/SOF compared to current treatment options 
and ‘no treatment’ in England and Wales. MethOds: A Markov model with a 
lifetime horizon was constructed in Microsoft Excel® to assess cost-effectiveness 
of LDV/SOF. Cost-effectiveness was assessed separately for treatment-naïve (TN) 
and experienced (TE) patients with CHC genotype 1 (GT1) or 4 (GT4). Cycle lengths 
were monthly (first 18 cycles), three-monthly (until year 2), and yearly (year 3 
onwards; half-cycle correction applied from year 3). Costs and utilities were dis-
counted at 3.5%; data were sourced from published literature. Patients could enter 
the model in a non-cirrhotic or cirrhotic disease state. For each cycle, patients 
remained in their current health state, achieved a sustained virological response 
(equivalent to a cure), progressed to more severe disease or died. General popu-
lation mortality was applied in each health state. An excess mortality risk was 
associated with advanced liver disease (decompensated cirrhosis, hepatocellular 
carcinoma, and liver transplantation). Cost-effectiveness was assessed using the 
incremental cost-effectiveness ratio (ICER), expressed as cost per quality adjusted 
life year (QALY). Results: In GT1 TN patients without cirrhosis (8 weeks LDV/SOF 
treatment) and GT4 TN patients without cirrhosis (12 weeks LDV/SOF treatment), 
LDV/SOF was cost-effective for all comparators with ICERs of £8,894 and £22,676 
versus the next most effective non-dominated option, respectively. In GT1 or GT4 
TN patients with cirrhosis, TE patients without cirrhosis, and TE patients with 
cirrhosis, 12 week LDV/SOF was associated with ICERs of £4,518, £16,566, and 
£5,435 versus no treatment, respectively; all active comparators were dominated 
or extendedly dominated. cOnclusiOns: LDV/SOF represents a cost-effective 
option versus established practice for GT1 and GT4 TN and TE patients with and 
without cirrhosis.
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tEstINg for Ns5a rEsIstaNcE IN ordEr to oPtImIZE aNtIvIral thEraPy 
wIth sImEPrEvIr aNd sofosbuvIr 12 wEEks aPPEars cost-EffEctIvE IN 
NoN-cIrrhotIc gENotyPE 1 hEPatItIs c vIrus trEatmENt ExPErIENcEd 
PatIENts
Westerhout KY1, Bouwmeester W1, Duchesne I2, Sbarigia U3, Pisini M2, Treur M1
1Pharmerit International, Rotterdam, The Netherlands, 2Janssen EMEA, Beerse, Belgium, 3Janssen 
Global Services, Beerse, Belgium
Objectives: Sustained virologic response (SVR) of NS5A inhibitor-containing 
regimens is reduced in genotype-1 hepatitis C virus (HCV) patients with NS5A 
resistance. The long-term persistence of NS5A resistance limits re-treatment 
options (Wyles et al, 2015). Latest EASL treatment guidelines recommend 
simeprevir+sofosbuvir with/without ribavirin (SMV+SOF±R) for re-treating 
patients failing a NS5A inhibitor-containing regimen. This study investigates 
the cost-effectiveness of NS5A resistance-testing (before treatment) to optimize 
treatment choice and avoid the need for re-treatment. MethOds: An existing 
lifetime Markov model was used to estimate disease progression for HCV genotype 
1 patients in the UK. Patient subgroups were identified by cirrhosis stage and prior 
treatment experience. NS5A resistance-testing pre-treatment and subsequent 
treatment with SMV+SOF or sofosbuvir+ledipasvir (SOF+LDV±R) in patients with 
or without NS5A resistance, respectively, was compared to a ‘no testing’ scenario 
where all patients received SOF+LDV±R. SVR rates of SOF+LDV±R in patients with/
without NS5A resistance were obtained from pooled phase II/III studies. SMV+SOF 
SVR rates, not impacted by NS5A resistance, were sourced from the OPTIMIST 
studies. Patient characteristics, HCV progression, mortality, resource utilization, 
unit costs and quality of life data were obtained from published sources. Results: 
Testing for NS5A and optimizing therapy to SMV+SOF (for patients with NS5A 
resistance pre-treatment) yielded 0.127 additional QALYs and increased costs 
with ~£2000 per patient (both 3.5% discounted), resulting in an incremental cost-
effectiveness ratio (ICER) of ~£15K versus ‘no testing’ in treatment experienced 
patients without cirrhosis. In these non-cirrhotic patients, optimizing therapy 
to receive 24 weeks of SOF+LDV±R in NS5A positive patients led to an ICER of 
> 100K compared to optimizing with 12 weeks of SMV+SOF. cOnclusiOns: 
NS5A resistance testing pre-treatment and subsequent optimizing therapy 
with SMV+SOF 12 weeks instead of SOF+LDV±R 12 weeks appeared to be 
cost-effective in treatment-experienced HCV patients without cirrhosis and 
with NS5A resistance. Optimizing with SOF+LDV±R 24 weeks was not deemed 
cost-effective.
